Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Study sponsor: Coherus Oncology, Inc. · CHRS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-05Actual
Enrollment · participants16Actual
Source updated2025-05-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.